Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various... see more

Recent & Breaking News (TSXV:TLT)

Theralase(R) Expands Clinical Team

ACCESS Newswire May 2, 2024

Theralase advances cancer research after private placement

Jonathon Brown April 24, 2024

Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement

ACCESS Newswire April 24, 2024

This company’s Photo Dynamic Therapy is transforming cancer treatment

Jocelyn Aspa April 9, 2024

Theralase patents new cancer vaccine in Canada

Trevor Abes  April 5, 2024

Theralase(R) Granted Canadian Cancer Vaccine Patent

ACCESS Newswire April 5, 2024

Theralase(R) Release's 4Q2023 Interim Financial Statements

ACCESS Newswire March 27, 2024

Theralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association

ACCESS Newswire March 26, 2024

Theralase donates laser therapy tech to help research Parkinson’s treatment

Jonathon Brown February 12, 2024

Theralase(R) Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson's Disease

ACCESS Newswire February 12, 2024

Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

ACCESS Newswire February 8, 2024

Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement

ACCESS Newswire February 5, 2024

Theralase provides encouraging bladder cancer study results

Jocelyn Aspa January 15, 2024

Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study

ACCESS Newswire January 15, 2024

Theralase Release's 3Q2023 Interim Financial Statements

ACCESS Newswire November 29, 2023

Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement

ACCESS Newswire November 29, 2023

Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing

ACCESS Newswire November 17, 2023

Theralase(R) Announces Brokered LIFE Financing

ACCESS Newswire October 23, 2023

Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study

ACCESS Newswire October 23, 2023

Theralase(R) Provides Update on Bladder Cancer Clinical Study

ACCESS Newswire October 16, 2023